Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Innovative Model
66%
Model Virus
66%
Glioblastoma
66%
Oncolytic Virus
66%
CIITA
33%
Adenovirus
33%
Patient-derived Organoids
22%
Organoids
11%
Immune Cell Co-culture
11%
Genetic Transfer
11%
Immunological Approaches
11%
Clinical Test
11%
Parvovirus
11%
Patient-specific
11%
Single-cell Technologies
11%
Immunological Response
11%
Efficacy Study
11%
Expected Outcomes
11%
In Vivo Model
11%
Promising Strategies
11%
Anticancer Activity
11%
Cancer Cells
11%
Inhuman
11%
Antitumor Immune Response
11%
Clinically Significant
11%
Viral Vectors
11%
Oncolytic
11%
Surgical Specimen
11%
Clinical Trials
11%
Tumor Cells
11%
Immune Response
11%
Ex Vivo Model
11%
High-throughput
11%
Immunocompromised Patients
11%
Co-culture Model
11%
Vector-based
11%
Recent Advances
11%
Brain Tumor
11%
HLA Class II
11%
Oncolytic Properties
11%
Epigenetic Profiling
11%
Chimera
11%
H-1 Parvovirus
11%
Genetics/epigenetics
11%
Immunovirotherapy
11%
Anti-GBM Disease
11%
Organoid Co-culture
11%
Organoid Development
11%
GBM Organoids
11%
Immune Therapy
11%
Effective Treatment
11%
Immune Checkpoint Inhibitors
11%
Glioblastoma Organoids
5%
Immunology and Microbiology
Oncolytic Virus
100%
Immunotherapy
100%
Organoid
83%
Adenoviridae
50%
CIITA
50%
Coculture
50%
Parvoviridae
33%
Immune Response
33%
Viral Vector
16%
Gene Transfer
16%
Virotherapy
16%
Immunocompetent Cell
16%
Intravenous Immunoglobulin
16%
Tumor Cell
16%
Antineoplastic Activity
16%
Cancer Cell
16%
Immune Checkpoint Inhibitor
16%
Biochemistry, Genetics and Molecular Biology
Virus
100%
CIITA
50%
Coculture
50%
Adenoviridae
50%
Genetics
33%
Parvoviridae
33%
Immune Response
33%
Intravenous Immunoglobulin
16%
Cancer Cell
16%
Antineoplastic Activity
16%
Clinical Trial
16%
Immunocompetent Cell
16%
Efficacy Study
16%
Virus Vector
16%
Immune Checkpoint Inhibitor
16%